Prognostic Impact Of Progastrin Levels In Blood Compared To MSKCC Based Clinical Prognosis In Metastatic Renal Cell Cancer Patients

Manish Kohli,1, Winston Tan2, Léa Payen1, Carole Langlois-Jacques4, Pierre Liaud1, Delphine Maucort-Boulch1, Dominique Joubert1 and Alexandre Prieur1. 1 Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, 2 Mayo Clinic, Florida, 3 Laboratoire de Biochimie et Biologie Moléculaire; Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL); CITOHL; Centre Hospitalier Lyon-Sud; Lyon; France, 4 Hospices Civils de Lyon, Service de Biostatistiques et Bioinformatique, F-69003 Lyon, France; Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 Villeurbanne, France. 5 Eurobiodev, 2040 avenue du Père Soulis, 34000 Montpellier, France. 4ECS-Progastrin, chemin de la Meunière 12, 1008 Prilly, Suisse.

Abstract

Background and Aims: Progastrin is a tumor promoting peptide which is detectable in the blood of patients with different cancers (Prieur et al. AARC 2017, Prieur et al. ASCO 2017). Progastrin gene is a direct target of the WNT5A-catenin oncopathic pathway involved in tumorigenesis of many organs, but it is unknown if it has any prognostic significance in metastatic renal cell cancer (mRCC) patients. We evaluated progastrin as a prognosis marker along with known markers of prognosis in mRCC.

Methods: 144 patients with mRCC were enrolled in this study and blood samples were drawn after consent. Progastrin was measured using the ELISA cancerREAD®. Progastrin concentrations in the 144 mRCC patients (test set) was assessed against 213 samples from asymptomatic volunteers from the French blood establishment (control set). The prognostic impact of progastrin levels was determined with overall survival (OS) using Cox proportional hazards and also compared to MSKCC based clinical prognosis (good; intermediate; poor). Statistical significance was considered at P<0.05.

Results: The median follow-up of the cohort was 5.45 years (IQR: 1.87-9.05) and at the time of analysis 98/144 patients had died from disease progression. Plasma progastrin was detected in 95% of the patients (cut-off value 1 pM; range 0 to 272 pM, median value of 7.2 pM; IQR 3.20-19.71) compared to the control set (median value=0.43 pM; IQR 0.00-1.51). The Receiver Operating Characteristic analysis indicated an area under the curve of 0.91 (p<0.0001; 95% Cl 0.88 to 0.94). At the univariate level, MSKCC scores (good; intermediate; poor categories) in this cohort was associated with OS and was prognostic (p<0.0001). We detected progastrin levels were higher with MSKCC score poor prognostic (p<0.0002) (median 30.39 pM; IQR 9.31-57.20). Elevated progastrin was also independently associated with poor survival (p<0.0001) and a multivariate model of MSKCC taken with progastrin levels remained significantly associated with poor survival (p<0.0001).

Conclusion: Elevated progastrin levels in mRCC is correlated with poor survival and further refines clinically used MSKCC prognostic scores. Progastrin assay is a simple and inexpensive blood test that might define subsets of mRCC patients with poor survival who need to be identified for aggressive treatments.

Methods

Patient Methods

A large tertiary level, clinically annotated hospital registry with prospective blood/plasma collection from adenocarcinoma patients between 5/2011 and 9/2013 and uniform sampling was used. Advanced kidney cancer patients were followed until death.

Analytical Methods

Each plasma EDTA sample was tested in duplicate using 50 µl of plasma using cancerREAD lab test (ECS-Progastrin) following manufacturer’s instructions.

Statistical Methods

Comparisons between groups were performed using the t-test. The statistics were performed with two-sided 5% alpha risks. The Bonferroni–Holm correction was used for multiple comparisons. The Kaplan Meier curves were compared and the logrank test. The following programs were used to perform the statistical analyses: Prism software (GraphPad, La Jolla, CA, USA); SAS version 9.4 ® software. Graphics were performed using R software version 3.4.4.

RESULTS: Study Demographics

<table>
<thead>
<tr>
<th>Prognostic Score</th>
<th>MSKCC Score</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>54</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>26</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
</tbody>
</table>

A. Progastrin levels were higher with MSKCC score poor prognostic (p=0.0002) (median 30.39 pM; IQR 9.31-57.20).

B. Descriptive analysis according MSKCC score.

Conclusions

1. Progastrin was detected in majority (95%) of the kidney cancer patients.
2. Elevated progastrin levels in mRCC is correlated with poor survival and further refines clinically used MSKCC prognostic scores.
3. Progastrin assay might be useful for defining subsets of mRCC patients with poor survival who need to be treated aggressively.